Treatment results in remission for about 85% of patients with antineutrophil cytoplasmic antibody (ANCA)-associated small-vessel vasculitis; however, 11–57% of these suffer relapse, which can ...

EGPA is a rare autoimmune disease characterized by vasculitis affecting small to medium sized blood vessels. NS-229 is an investigational selective Janus kinase 1 (JAK1) inhibitor designed to ...